Dublin, Dec. 23, 2016 -- Research and Markets has announced the addition of the "Global Pharmaceutical Contract Manufacturing Market 2016-2020" report to their offering.
The global pharmaceutical contract manufacturing market to grow at a CAGR of 6.91% during the period 2016-2020.
The report covers the present scenario and the growth prospects of the global pharmaceutical contract manufacturing market for 2016-2020. To calculate the market size, the report considers the revenue generated from various pharmaceutical drug manufacturing outsourcing activities. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One of latest trends in the market is consolidation through vertical integration, alliances, and acquisitions. The major pharmaceutical companies have decreased their operations and R&D budgets, which has led to an increase in demand for outsourced services. Moreover, companies have consolidated their infrastructure in response to a sharp global economic downturn, poor revenue growth prospects, and expensive and inefficient operations.
Strategic partnerships between pharmaceutical companies and CMOs have led to the reduction of government spending on manufacturing. The past few years have brought major changes to the pharmaceutical outsourcing services. As more in-house positions have been removed, pharmaceutical vendors are looking for strategic partnerships and 'one-stop' solutions.
Further, the report states that one major challenge in the market is lack of information integration. One of the greatest challenges faced by most vendors in the pharmaceutical contract manufacturing market is the lack of transparency and information integration in the whole supply chain process. Few medicines, especially vaccines and specialty injections, need fast delivery to ensure their utility. If companies are equipped with a centralized system, they will be able to observe changes in inventory and can order shipments as per requirements. Distribution vehicles or shipments can be redirected to obtain drugs in the required areas.
With the right integration of available data from all the stages within the supply chain, companies can keep track of orders and delivery rates. This can effectively cure the delays and disruptions in the pharmaceutical supply chain, making the entire value chain effectively responsive to the unmet medical needs.
Key vendors
- Catalent
- Lonza
- Pfizer CentreOne
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Pharmaceutical manufacturing outsourcing
Part 06: Market landscape
Part 07: Market segmentation by type of contract manufacturing
Part 08: Geographical segmentation
Part 09: Key leading countries
Part 10: Market drivers
Part 11: Impact of drivers
Part 12: Market challenges
Part 13: Impact of drivers and challenges
Part 14: Market trends
Part 15: Vendor landscape
Part 16: Key vendor analysis
Part 17: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/mhzdln/global
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals, Pharmaceutical Manufacturing


Samsung Electronics Shares Jump on HBM4 Mass Production Report
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 



